Publications by authors named "Ryan Dorton"

Claim this Profile
P
Prostate-Specific Membrane Antigen-Specific Antitumor Activity of a Self-Immolative Tubulysin Conjugate.
Christopher P Leamon, Joseph A Reddy, Alicia Bloomfield, Ryan Dorton, Melissa Nelson

Bioconjug Chem· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pre-clinical evaluation of EC1456, a folate-tubulysin anti-cancer therapeutic.
Joseph A Reddy, Ryan Dorton, Alicia Bloomfield, Melissa Nelson, Christina Dircksen

Sci Rep· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enhancing the therapeutic range of a targeted small-molecule tubulysin conjugate for folate receptor-based cancer therapy.
Christopher P Leamon, Joseph A Reddy, Iontcho R Vlahov, Ryan Dorton, Alicia Bloomfield

Cancer Chemother Pharmacol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High Levels of Expression of P-glycoprotein/Multidrug Resistance Protein Result in Resistance to Vintafolide.
Amy D Guertin, Jennifer O'Neil, Alexander Stoeck, Joseph A Reddy, Razvan Cristescu, Ryan Dorton

Mol Cancer Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rational combination therapy of vintafolide (EC145) with commonly used chemotherapeutic drugs.
Joseph A Reddy, Ryan Dorton, Alicia Bloomfield, Melissa Nelson, Marilynn Vetzel

Clin Cancer Res· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate-vinca alkaloid conjugates for cancer therapy: a structure-activity relationship.
Christopher P Leamon, Iontcho R Vlahov, Joseph A Reddy, Marilynn Vetzel, Hari Krishna R Santhapuram, Ryan Dorton

Bioconjug Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing undesirable hepatic clearance of a tumor-targeted vinca alkaloid via novel saccharopeptidic modifications.
Christopher P Leamon, Joseph A Reddy, Patrick J Klein, Iontcho R Vlahov, Ryan Dorton

J Pharmacol Exp Ther· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
In vivo structural activity and optimization studies of folate-tubulysin conjugates.
Joseph A Reddy, Ryan Dorton, Alicia Dawson, Marilynn Vetzel, Nikki Parker

Mol Pharm· December 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of high and low folate diets on tissue folate receptor levels and antitumor responses toward folate-drug conjugates.
Christopher P Leamon, Joseph A Reddy, Ryan Dorton, Alicia Bloomfield, Kristen Emsweller

J Pharmacol Exp Ther· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Folate targeting enables durable and specific antitumor responses from a therapeutically null tubulysin B analogue.
Christopher P Leamon, Joseph A Reddy, Marilynn Vetzel, Ryan Dorton, Elaine Westrick

Cancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical antitumor activity of a novel folate-targeted dual drug conjugate.
Christopher P Leamon, Joseph A Reddy, Iontcho R Vlahov, Elaine Westrick, Alicia Dawson, Ryan Dorton

Mol Pharm· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate.
Joseph A Reddy, Ryan Dorton, Elaine Westrick, Alicia Dawson, Terri Smith

Cancer Res· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis